Lectures and posters by country (2013-2023) [Only countries featuring at least 25 contributions] (Abbreviations: US: United States of America, BR: Brazil, MX: Mexico, KR: South Kor... حسب Ignacio García-Espona (21395335)

الموضوعات:

Posters by gender. حسب Ignacio García-Espona (21395335)

الموضوعات:

Correlogram of the relationships among the variables. حسب Ignacio García-Espona (21395335)

الموضوعات:

Thematic clouds for lectures. حسب Ignacio García-Espona (21395335)

الموضوعات:

Efficiency analysis of various countries [left column: countries ordered according to our national global indicator; central column: countries ordered according to the number of le... حسب Ignacio García-Espona (21395335)

الموضوعات:

Comparison cloud indicating the words that appeared most frequently with regard to each type of lecturer (lecturers from the USA, top, blue colour; lecturers not from the USA, bott... حسب Ignacio García-Espona (21395335)

الموضوعات:

Global number of lectures and posters (2013-2023). حسب Ignacio García-Espona (21395335)

الموضوعات:

Comparison cloud for posters indicating the words that appeared most frequently in each period (2013-2017, top, blue colour; 2018-2023, bottom, red colour). حسب Ignacio García-Espona (21395335)

الموضوعات:

Poster ratios (women/men) by country and year [Top 10 countries] (Abbreviations: AU: Australia, BR: Brazil, CA: Canada, CN: China, DE: Germany, IT: Italy, JP: Japan, KR: South Kore... حسب Ignacio García-Espona (21395335)

الموضوعات:

Lectures by country and year [Top 10 countries] (Abbreviations: AU: Australia, BR: Brazil, CA: Canada, CN: China, DE: Germany, IT: Italy, JP: Japan, KR: South Korea, TW: Taiwan, US... حسب Ignacio García-Espona (21395335)

الموضوعات:

Lectures by country and year [Top 2-10 countries] (Abbreviations: AU: Australia, BR: Brazil, CA: Canada, CN: China, DE: Germany, IT: Italy, JP: Japan, KR: South Korea, TW: Taiwan). حسب Ignacio García-Espona (21395335)

الموضوعات:

Lecturer ratios (women/men) by country and year [Top 10 countries] (Abbreviations: AU: Australia, BR: Brazil, CA: Canada, CN: China, DE: Germany, IT: Italy, JP: Japan, KR: South Ko... حسب Ignacio García-Espona (21395335)

الموضوعات:

Sample Data. حسب Ignacio García-Espona (21395335)

الموضوعات:

Variations in the prevalence of OASI in France between 2010 and 2021 according to the classification for episiotomy practices. حسب Raphaele Houlbracq (20558509)

الموضوعات:

Trends in the characteristics of women giving birth vaginally in France between 2010 and 2021. حسب Raphaele Houlbracq (20558509)

الموضوعات:

Variations in the prevalence of episiotomy in France between 2010 and 2021 according to the classification for episiotomy practices. حسب Raphaele Houlbracq (20558509)

الموضوعات:

Flow chart. حسب Raphaele Houlbracq (20558509)

الموضوعات:

pmed.1004501.t001 - Episiotomies and obstetric anal sphincter injuries following a restrictive episiotomy policy in France: An analysis of the 2010, 2016, and 2021 National Perinat... حسب Raphaele Houlbracq (20558509)

الموضوعات:

Table 2_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx حسب Tengxiang Zhao (20749475)

"…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…"

Table 1_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx حسب Tengxiang Zhao (20749475)

"…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…"